말라리아 백신 시장 : 백신 유형, 연령층, 투여 스케줄, 최종 사용자, 투여 경로별 - 세계 시장 예측(2026-2032년)

The Malaria Vaccine Market is projected to grow by USD 623.32 million at a CAGR of 8.79% by 2032.

The malaria vaccine market is entering a defined scale-up phase as immunization moves from long-running pilot programs into national childhood vaccination schedules. The need is measurable: the World Health Organization reported an estimated 263 million malaria cases and 597,000 deaths in 2023, with children under five in sub-Saharan Africa bearing the highest mortality burden.

Two WHO-recommended malaria vaccines now shape the competitive and public health landscape: RTS,S/AS01 and R21/Matrix-M. Their adoption is expanding the role of vaccine manufacturers, global health funders, national malaria control programs, cold-chain providers, and surveillance partners in an ecosystem that remains closely tied to insecticide-treated nets, seasonal malaria chemoprevention, diagnostics, and antimalarial treatment.

Transformative Shifts in the Malaria Vaccine Landscape

The most important shift is the transition from proof of concept to programmatic delivery. WHO's 2021 recommendation of RTS,S/AS01 and 2023 recommendation of R21/Matrix-M created a two-vaccine environment, improving procurement flexibility and increasing confidence among endemic countries planning phased malaria vaccine rollouts.

Market dynamics are also changing as demand is driven less by private-pay channels and more by public immunization budgets, Gavi-supported introductions, UNICEF procurement, and ministries of health. Climate variability, insecticide resistance, urban transmission, and population mobility are increasing the importance of integrated malaria prevention strategies, positioning vaccines as a complementary tool rather than a standalone intervention.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the malaria vaccine value chain by accelerating antigen discovery, improving protein-structure modeling, and supporting immune-response analysis across complex parasite life-cycle stages. These capabilities are relevant because Plasmodium falciparum has biological complexity that has historically made vaccine development difficult.

AI is also strengthening operational execution. Predictive analytics can support clinical trial-site selection, adverse-event signal detection, supply planning, and cold-chain optimization in areas where seasonal transmission creates sharp fluctuations in need. For manufacturers and public health agencies, the cumulative impact is faster decision-making, better allocation of limited doses, and more targeted post-introduction surveillance.

Key Regional Insights: Asia-Pacific, Africa, Europe, and the Americas

Africa remains the center of malaria vaccine demand because WHO attributes about 94% of global malaria cases and 95% of malaria deaths to the African region. Routine introductions in countries such as Cameroon and broader Gavi-supported expansion are making the region the primary proving ground for vaccine delivery, safety monitoring, community acceptance, and real-world effectiveness in children.

Asia-Pacific has a mixed profile: India and parts of Southeast Asia continue to manage malaria transmission, while China has achieved WHO malaria-free certification, creating a region that combines disease-control needs with vaccine manufacturing and research capabilities. North America and Europe are primarily innovation, funding, regulatory, and travel-medicine hubs that support malaria vaccine development, evaluation, and global health financing. Latin America's need is concentrated in Amazon basin transmission pockets, while the Middle East has selective risk areas and procurement relevance through humanitarian and global health financing. Africa remains the largest demand pool, but global participation is distributed across R&D, production, financing, regulation, and implementation.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN countries face heterogeneous malaria risk, with higher relevance in border, forest, and migrant-worker settings than in highly urbanized markets, making surveillance, targeted immunization planning, and cross-border coordination important. GCC countries are less exposed to domestic malaria burden but remain relevant through travel health, humanitarian assistance, sovereign health investments, and support for disease-control programs in endemic regions.

The European Union and G7 are central to research funding, regulatory science, manufacturing partnerships, and global procurement support for malaria vaccines. BRICS brings together both high-burden and high-capacity markets, notably India's disease-control and vaccine-production role, China's elimination experience and manufacturing capacity, and Brazil's Amazon-focused malaria challenge. NATO is not a malaria market grouping, yet member countries contribute through military medicine, deployment health, outbreak preparedness, and global health security financing that can support vaccine readiness in endemic regions.

Key Country Insights Across Major Malaria Vaccine Markets

The United States and Canada are primarily R&D, donor, travel-medicine, and regulatory markets, while Mexico continues to focus on elimination-oriented surveillance and outbreak prevention. Brazil is the most important listed Latin American country for malaria vaccine relevance because transmission is concentrated in the Amazon region, where access, mobility, and surveillance challenges shape prevention strategies.

In Europe, the United Kingdom, Germany, France, Italy, and Spain contribute through research institutions, development finance, regulatory expertise, vaccine science, and imported malaria management, while Russia has limited endemic-market relevance but retains scientific and regional health capacity. China's WHO-certified malaria-free status strengthens its role in surveillance, elimination experience, and manufacturing; India remains central due to its malaria burden, national control efforts, and vaccine industry capacity. Japan, Australia, and South Korea contribute through biomedical R&D, financing, regional health-security programs, and partnerships supporting malaria control across Asia-Pacific.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize endemic-country access strategies, including predictable pricing, technology transfer, and supply commitments aligned with national immunization schedules. Manufacturers must design capacity plans around phased rollout, seasonality, country readiness, and procurement cycles rather than conventional commercial demand alone.

Leaders should also invest in pharmacovigilance, implementation research, and combination prevention evidence that demonstrates how malaria vaccines perform alongside insecticide-treated nets, chemoprevention, diagnostics, and case management. Strategic partnerships with global health agencies, immunization financiers, procurement bodies, African ministries of health, and local manufacturers will be essential to building trust, accelerating adoption, and reducing delivery bottlenecks.

Research Methodology

This executive summary is built from verified secondary research and market triangulation using publicly available evidence from WHO malaria reporting, WHO vaccine recommendations, vaccine introduction materials, procurement context from multilateral immunization channels, peer-reviewed vaccine studies, and national malaria control information.

The analysis evaluates epidemiology, policy adoption, product availability, funding pathways, manufacturing capacity, regulatory direction, and regional disease burden. Insights are cross-checked against multiple authoritative sources to avoid unsupported market claims, market sizing, or forecasting, and to ensure that conclusions reflect current malaria vaccine science, public health implementation, and procurement realities.

Conclusion

The malaria vaccine market is no longer theoretical. WHO-recommended products, expanding national introductions, and global financing mechanisms are turning malaria immunization into a practical tool for reducing childhood morbidity and mortality in high-burden settings.

Progress will depend on sustained evidence generation, affordable supply, country readiness, community acceptance, and integration with established malaria control measures. Organizations that combine scientific innovation with equitable access, reliable delivery, and strong surveillance will be best positioned to shape the next phase of malaria vaccine impact.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Malaria Vaccine Market, by Vaccine Type

• 7.1. Conjugate Vaccine
• 7.2. Live Attenuated Vaccine
• 7.3. Mrna Vaccine
  • 7.3.1. Conventional Mrna
  • 7.3.2. Self Amplifying Mrna
• 7.4. Subunit Vaccine
• 7.5. Viral Vector Vaccine
  • 7.5.1. Adenovirus Vector
  • 7.5.2. Mva Vector

8. Malaria Vaccine Market, by Age Group

• 8.1. Adolescent & Adult
• 8.2. Child
  • 8.2.1. Preschool
  • 8.2.2. School Age
• 8.3. Infant

9. Malaria Vaccine Market, by Dosage Schedule

• 9.1. Single Dose
• 9.2. Three Dose
• 9.3. Two Dose

10. Malaria Vaccine Market, by End User

• 10.1. NGOs
• 10.2. Private Clinics
• 10.3. Public Immunization Programs
  • 10.3.1. Local Programs
  • 10.3.2. National Programs

11. Malaria Vaccine Market, by Route Of Administration

• 11.1. Intramuscular
• 11.2. Oral
• 11.3. Subcutaneous

12. Malaria Vaccine Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Malaria Vaccine Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Malaria Vaccine Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AstraZeneca plc
• 16.2. Bharat Biotech International Limited
• 16.3. BioNTech SE
• 16.4. Emergent BioSolutions Inc.
• 16.5. GSK plc
• 16.6. Instituto Butantan
• 16.7. Johnson & Johnson
• 16.8. Merck & Co., Inc.
• 16.9. Moderna, Inc.
• 16.10. Novavax, Inc.
• 16.11. PathWest Laboratory Medicine WA
• 16.12. Pfizer Inc.
• 16.13. Sanofi S.A.
• 16.14. Serum Institute of India Private Limited
• 16.15. Takeda Pharmaceutical Company Limited
• 16.16. Valneva SE